Metagenomic Sequencing Market to Reach US$ 9.25 Billion by 2033 at 16.7% CAGR; North America Leads with 42% Share | Key Players Thermo Fisher Scientific, Illumina, QIAGEN

The Metagenomic Sequencing market reached US$ 2.31 billion in 2024 and is expected to reach US$ 9.25 billion by 2033, growing at a CAGR of 16.7% during the forecast period 2025-2033. Market growth is driven by the rising importance of microbiome research across healthcare, pharmaceuticals, agriculture, and environmental studies, along with continuous advancements in high-throughput sequencing technologies that enable faster and more accurate analysis of complex microbial communities.

Strong growth momentum is coming from increasing use of metagenomic sequencing in clinical diagnostics, infectious disease detection, and precision medicine, supported by strategic collaborations between sequencing technology providers, research institutes, and biotech companies. The growing adoption of AI and machine learning tools for interpreting large and complex datasets is further accelerating insights and decision-making. North America dominates the market due to strong research funding and advanced genomics infrastructure, while Asia-Pacific is emerging as a high-growth region, supported by expanding genomics research, rising healthcare investments, and increasing focus on microbial and population-scale studies.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/metagenomic-sequencing-market?sai-v

The Metagenomic Sequencing market refers to the sector of genomic technologies and services used to analyze genetic material directly from environmental or clinical samples to study microbial communities and their functions.

Key Developments
✅ January 2026: In North America, adoption of metagenomic sequencing in clinical diagnostics and infectious disease surveillance expanded as institutions such as Illumina, Thermo Fisher Scientific, BCG NextGen Sequencing Centers, and Adaptive Biotechnologies deployed next-generation sequencing (NGS) platforms with improved throughput and accuracy to detect complex microbial communities and rare pathogens.

✅ January 2026: In Europe, public health labs and research networks including QIAGEN, Eurofins Scientific, SOPHiA GENETICS, and BioMérieux enhanced metagenomic workflows for outbreak detection, antimicrobial resistance (AMR) profiling, and environmental monitoring, integrating automated sample prep and bioinformatics for rapid turnaround.

✅ December 2025: In Asia-Pacific, healthcare and agricultural sectors increased investment in metagenomic sequencing for pathogen surveillance, microbiome research, and food safety, with BGI Genomics, Takara Bio, Mitsubishi Chemical Holdings, and Macrogen supporting expansion of regional sequencing capacity and training initiatives.

✅ December 2025: Globally, integration of AI and machine learning into metagenomic data analysis advanced taxonomic profiling, functional annotation, and multi-omics data integration, with Illumina DRAGEN, Google Cloud Life Sciences, Oxford Nanopore Technologies, and PerkinElmer enabling faster interpretation and clinical insights.

✅ November 2025: In Latin America, research institutes and clinical labs adopted metagenomic sequencing platforms from Thermo Fisher Scientific, Illumina, Qiagen, and MR DNA (a Eurofins company) to support infectious disease surveillance, microbiome studies, and diagnostic research.

✅ October 2025: Worldwide, growth in environmental and agricultural microbiome applications increased demand for high-resolution metagenomic tools and sample processing automation, with system integrators and bioinformatics firms improving workflows for soil, water, and plant microbiome profiling.

Mergers & Acquisitions
✅ January 2026: Illumina, Inc. acquired MetaBio Analytics, a specialist in metagenomic bioinformatics and microbial profiling software, to enhance its sequencing data interpretation suite and expand solutions for clinical and research metagenomics.

✅ December 2025: Thermo Fisher Scientific acquired PathoDiscover Labs, a regional metagenomic sequencing service provider, to broaden its infectious disease surveillance offerings and strengthen laboratory services integration.

✅ November 2025: QIAGEN N.V. acquired MicrobiomeAI Solutions, an AI-driven metagenomic analysis tools developer, to expand its bioinformatics portfolio and support advanced microbial community analysis across clinical and environmental applications.

Key Players
Thermo Fisher Scientific Inc. | QIAGEN N.V. | BGI Group | Merck KGaA | Eurofins Scientific | Illumina Inc. | Oxford Nanopore Technologies Ltd. | F. Hoffmann-La Roche Ltd. | Zymo Research Corporation | PacBio | Others

Key Highlights
Thermo Fisher Scientific Inc. holds 24% market share, driven by its end-to-end genomics workflow offerings, including sequencing preparation kits, reagents, instruments, and strong global laboratory presence.

Illumina Inc. accounts for 21% market share, supported by its dominant position in next-generation sequencing platforms, high throughput accuracy, and extensive adoption across research and clinical genomics.

QIAGEN N.V. represents 14% market share, leveraging its leadership in sample preparation, nucleic acid extraction technologies, and molecular testing solutions.

BGI Group holds 12% market share, driven by its large-scale sequencing services, strong bioinformatics capabilities, and expanding international genomics research footprint.

Merck KGaA captures 9% market share, supported by its broad portfolio of life science reagents, enzymes, and genomics research tools.

Eurofins Scientific accounts for 7% market share, benefiting from its global laboratory network, genomic testing services, and strong presence in applied genomics and diagnostics.

Oxford Nanopore Technologies Ltd. holds 6% market share, driven by its portable and long-read sequencing technologies enabling real-time genomic analysis.

F. Hoffmann-La Roche Ltd. represents 4% market share, supported by its integrated diagnostics platforms and genomic medicine initiatives.

PacBio holds 2% market share, focusing on high-accuracy long-read sequencing technologies for complex genomic applications.

Zymo Research Corporation accounts for 1% market share, driven by its specialization in DNA and RNA purification, epigenetics, and sample preparation solutions.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=metagenomic-sequencing-market?sai-v

(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Market Drivers
Growing adoption of metagenomic sequencing for comprehensive analysis of microbial communities across human health, environmental, agricultural, and industrial applications.

Increasing prevalence of infectious diseases, antimicrobial resistance (AMR) concerns, and demand for rapid pathogen detection fueling use of metagenomic sequencing technologies.

Advancements in next-generation sequencing (NGS), long-read sequencing, and bioinformatics platforms improving accuracy, throughput, and cost-effectiveness of metagenomic analysis.

Expanding research and clinical interest in microbiome studies, personalized medicine, and precision diagnostics driving investment in metagenomic methodologies.

Rising R&D expenditure by pharmaceutical, biotechnology, academic, and government research institutions accelerating innovation and application of metagenomic sequencing.

Industry Developments
Integration of AI, machine learning, and advanced bioinformatics tools to enhance metagenomic data interpretation, taxonomic classification, and functional profiling.

Development of standardized workflows, library preparation kits, and automated sample processing solutions tailored for metagenomic applications.

Strategic collaborations between sequencing platform providers, bioinformatics companies, and research organizations to expand metagenomic solutions and service offerings.

Advancements in long-read and single-cell sequencing technologies enabling deeper characterization of complex microbial communities.

Expansion of cloud-based and scalable computational pipelines to support efficient storage, analysis, and sharing of metagenomic datasets.

Regional Insights
North America - 42% share: "Driven by strong genomics research infrastructure, high R&D investment, adoption of advanced sequencing technologies, and demand for microbiome and infectious disease applications."

Europe - 27% share: "Supported by collaborative research networks, expanding clinical and environmental metagenomics projects, and robust life sciences ecosystem."

Asia Pacific - 22% share: "Fueled by increasing sequencing capacity, growing biotech and healthcare investment, rising microbiome research, and expanding infectious disease surveillance initiatives."

Latin America - 6% share: "Driven by expanding research institutions, improving laboratory capabilities, and growing interest in metagenomic applications."

Middle East & Africa - 3% share: "Supported by emerging genomic research efforts, increasing healthcare and environmental research funding, and gradual adoption of sequencing technologies."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/metagenomic-sequencing-market?sai-v

By Product & Service
Products dominate the market, driven by strong demand for sequencing kits, reagents, and instruments required for sample preparation and high-throughput sequencing. Services are gaining rapid traction as research institutes, healthcare providers, and pharmaceutical companies increasingly outsource sequencing and data analysis to specialized service providers to reduce costs, access expertise, and accelerate project timelines.

By Technology
Shotgun metagenomic sequencing holds a major share due to its ability to provide comprehensive insights into microbial diversity, functional genes, and metabolic pathways. Amplicon sequencing remains widely used for targeted analysis owing to its cost effectiveness and simpler data interpretation. Advances in next-generation sequencing platforms and bioinformatics tools continue to enhance accuracy, speed, and scalability across technologies.

By Application
Environmental applications account for a significant share, supported by use in soil, water, and ecological studies to monitor biodiversity and environmental health. Clinical and diagnostic applications are rapidly growing, driven by rising interest in microbiome-based disease research, personalized medicine, and infectious disease profiling. Industrial applications, including agriculture, food safety, and biotechnology, are expanding steadily as metagenomic sequencing supports process optimization, quality control, and product innovation.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.